Clinical trial
A Prospective, Multi-Center, Self-Controlled Phase IIa Clinical Trial Evaluating the Diagnostic Performance and Clinical Impact of [⁶⁸Ga]Ga-DLL3 Nanobody PET/CT Compared to [¹⁸F]FDG or [⁶⁸Ga]Ga-PSMA PET/CT in Patients With Metastatic Neuroendocrine Neoplasms
NCT07733024 is registered in ClinicalTrials.gov with Tingting Yuan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-Center, Self-Controlled Phase IIa Clinical Trial Evaluating the Diagnostic Performance and Clinical Impact of [⁶⁸Ga]Ga-DLL3 Nanobody PET/CT Compared to [¹⁸F]FDG or [⁶⁸Ga]Ga-PSMA PET/CT in Patients With Metastatic Neuroendocrine Neoplasms
- Lead sponsor
- Tingting Yuan
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 6, 2026
- Completion date
- December 31, 2028
- Enrollment
- 200 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.